ELECTION IN RESPONSE TO RESTRICTION REQUIREMENT

The Examiner has required that Applicant elect for initial prosecution an invention defined by one of the following six groups of claims:

- Claims 1-17, drawn to probes for detecting a nucleic acid, comprising fragments of SEQ ID NO:101;
- II. Claim 18-30, drawn to primer pairs for amplification of a nucleic acid, the first primer being a fragment of SEQ ID NO:73, and the second being a fragment of SEQ ID NO:59;
- III. Claims 31-44, drawn to probes for detecting a nucleic acid, comprising fragments of SEQ ID NO:99;
- IV. Claim 45-54, drawn to primer pairs for amplification of a nucleic acid, the first primer being a fragment of SEQ ID NO:52, and the second being a fragment of SEQ ID NO:41;
- Claims 55-67, drawn to probes for detecting a nucleic acid, comprising fragments of SEQ ID NO:95; and
- VI. Claims 68-82, drawn to primer pairs for amplification of a nucleic acid, the first primer being a fragment of SEQ ID NO:16, and the second being a fragment of SEQ ID NO:1.

Applicant hereby elects Group II, Claims 18-30 for initial prosecution. In response to the requirement for an Election of Species, Applicant hereby elects SEQ ID NO:75 as a fragment of SEQ ID NO:73, and SEQ ID NO:64 as a fragment of SEQ ID NO:59. Claims readable on these elections are reflected in the below-presented Listing of Claims which will remain pending following entry of this Response.

Non-elected Claims 1-17 and 31-82 have been canceled from the Application by Preliminary Amendment, hereinbelow.

AMENDMENTS TO THE CLAIMS

Preliminary to examination on the merits, please amend the above-captioned application in accordance with the following Listing of Claims. This Listing will replace all prior versions, and Listings, of claims in the Application.

Listing of Claims:

1-17 (Canceled)

18. (Original) A kit for amplifying a target nucleic acid sequence that may be present in a biological sample, comprising:

a first primer that comprises a 3' terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said first primer comprising 22 contiguous bases contained within SEQ ID NO:73, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences; and

a second primer that comprises a 3' terminal target-complementary sequence and optionally a second primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said second primer comprising 18 contiguous bases contained within SEQ ID NO:59, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

- 19. (Original) The kit of Claim 18, wherein said first primer and said second primer are each up to 60 bases in length.
- 20. (Original) The kit of Claim 18, wherein said 3' terminal target-complementary sequence of said first primer and said 3' terminal target-complementary sequence of said second primer are each up to 35 bases in length.

Page 3 of 5

Appl. Serial No. 10/688,489 Response dated Mar. 15, 2005 Reply to Office Action of Dec. 16, 2004

- 21. (Original) The kit of Claim 20, wherein said 3' terminal target-complementary sequence of said first primer is up to 24 bases in length.
- 22. (Original) The kit of Claim 20, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.
- 23. (Original) The kit of Claim 21, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.
- 24. (Original) The kit of Claim 23, wherein said first primer comprises said first primer upstream sequence.
- 25. (Original) The kit of Claim 24, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.
- 26. (Original) The kit of Claim 23, wherein said 3' terminal target-complementary sequence of said first primer is selected from the group consisting of SEQ ID NO:75, SEQ ID NO:76 and SEQ ID NO:77, and wherein said 3' terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:71.
- 27. (Original) The kit of Claim 21, wherein said 3' terminal target-complementary sequence of said first primer comprises 22 contiguous bases contained within SEQ ID NO:74, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.
- 28. (Original) The kit of Claim 27, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.
- 29. (Original) The kit of Claim 27, wherein said first primer comprises said first primer upstream sequence.
- 30. (Original) The kit of Claim 29, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

31-82 (Canceled)